论文部分内容阅读
目的:分析重症胰腺炎患者早期接受肠内营养支持治疗对预后的影响。方法:将我院与2013年5月至2014年5月确诊入院的40例重症胰腺炎患者作为研究对象,并将其随机分为两组,即研究组和对照组,每组各20例。我们对20名对照组患者进行常规治疗,即提供肠外营养;而对于另20名研究组患者采取同样的治疗措施,但在早期为患者提供了肠内营养支持治疗。我们将两组患者的相关生化指标的检测结果及住院时间、住院费用、并发症的发生率等多项数值进行了真实比对分析。结果:研究组和对照组在血清白蛋白、血糖与淀粉酶的检测结果在治疗前、后都没有明显变化(P>0.05);天冬氨酸转化酶在治疗后的检测结果显示研究组低于对照组(P<0.05);在住院时间、住院费用、并发症的发生几率方面研究组显著低于对照组(P<0.05)。结论:早期给予肠内营养支持是值得在临床上应用与推广的,不仅可以有效降低重症胰腺炎患者的天冬氨酸转化酶水平,同时患者住院花费少且恢复快,并发症的发生率也明显下降。
Objective: To analyze the influence of early enteral nutrition support on prognosis in patients with severe acute pancreatitis. Methods: Forty cases of severe pancreatitis admitted to our hospital from May 2013 to May 2014 were randomly divided into two groups: study group and control group, with 20 cases in each group. We routinely treated 20 patients in the control group with parenteral nutrition, while we took the same treatment for another 20 study patients, but enrolled patients with early enteral nutrition support. We compared the results of two biochemical indicators of patients with hospitalization time, hospitalization costs, the incidence of complications such as a number of true comparative analysis. Results: The results of serum albumin, blood glucose and amylase in the study group and the control group showed no significant changes before and after treatment (P> 0.05). The results of aspartate converting enzyme in the study group showed that the low In the control group (P <0.05). The study group was significantly lower than the control group in the length of hospital stay, hospitalization costs and complications (P <0.05). Conclusions: Early enteral nutrition support is worthy of clinical application and promotion. It not only can effectively reduce the aspartate invertase level in patients with severe pancreatitis, but also reduce the cost of inpatient hospitalization and fast recovery. The incidence of complications is also Significant decline.